Shahzad Shah, MD
Cardiovascular Disease · Jackson, TNNPI 1356528442
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $11,581 of the $14,729 with a category attached, or 78.6%. Medtronic accounts for 73.5% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $10,907, 6.2 times the $1,762 reported in 2019.
Across 168 payments — averaging $87.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$11K
- Corindus Inc.$2K
- Novartis$470
- E.r. Squibb & Sons, L.L.C.$407
- Edwards Lifesciences$318
- Pfizer$202
- plus $991 from 15 others
Across 21 payments — averaging $11,419 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$149K
- Amgen$47K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$44K
What the payments were for
- Travel & lodging$11,58179%
- Food & beverage$3,14821%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 28 | $10,820 |
| Corindus Inc. | 7 | $1,520 |
| Novartis | 51 | $470 |
| E.r. Squibb & Sons, L.L.C. | 23 | $407 |
| Edwards Lifesciences | 2 | $318 |
| Pfizer | 14 | $202 |
| Abbott | 3 | $200 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $180 |
| Terumo Medical Corporation | 1 | $154 |
| Novo Nordisk | 4 | $86 |
| Boehringer Ingelheim | 4 | $60 |
| Amgen | 3 | $47 |
| AstraZeneca | 2 | $47 |
| Abiomed | 1 | $43 |
| Alnylam Pharmaceuticals Inc. | 2 | $42 |
| GSK | 2 | $34 |
| Bridgebio Pharma, Inc. | 1 | $29 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Boston Scientific | 1 | $18 |
| Philips North America LLC | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$9,687
- CorPath GRX$1,490
- TurboHawk$425
- Edwards SAPIEN 3 Transcatheter Heart Valve$293
- GlideWire$154
- MitraClip$152
- CAMZYOS$108
- Micra$108
- COBALT DR MRI SURESCAN$102
How this compares
$14,729 in reported general payments places this provider in the 85th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 607 | $578,216 |
| EntrestoSacubitril/Valsartan | 213 | $206,141 |
| Repatha SureclickEvolocumab | 71 | $48,423 |
| XareltoRivaroxaban | 44 | $40,763 |
| FarxigaDapagliflozin Propanediol | 34 | $27,820 |
| JardianceEmpagliflozin | 21 | $15,828 |
| Praluent PenAlirocumab | 24 | $11,891 |
| Ranolazine ErRanolazine | 57 | $8,941 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 35 | $7,078 |
| Nebivolol Hcl | 36 | $5,300 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 412 | $4,978 |
| Atorvastatin Calcium | 397 | $4,677 |
| ClopidogrelClopidogrel Bisulfate | 432 | $4,391 |
| Losartan Potassium | 331 | $4,353 |
| Diltiazem 12hr ErDiltiazem Hcl | 15 | $3,662 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $202 | $578,216607 claims |
| NovartisEntresto | $470 | $206,141213 claims |
| AstraZenecaFarxiga | $47 | $27,82034 claims |
| Boehringer IngelheimJardiance | $60 | $15,82821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 429 cardiovascular disease providers in Tennessee.
Other cardiovascular disease in Jackson
- Adeyinka AgbetoyinJackson$112K
- Elliot KurbanJackson$68K
- Mohsin AlhaddadJackson$14K
- Alexander AlperovichJackson$13K
- Nirav PatelJackson$12K
- David MetzgerKingsport$555K
- Christopher EllisNashville$527K
- Joann LindenfeldNashville$270K
- Steven GubinMemphis$248K
- Andrew ZurickNashville$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.